Refractory Neoplasm
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| 9-ING-41 in Pediatric Patients With Refractory Malignancies. (NCT04239092) | Actuate Therapeutics Inc. | 2020-06-05 |
| 9-ING-41 in Patients With Advanced Cancers (NCT03678883) | Actuate Therapeutics Inc. | 2019-01-04 |
| Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers (NCT03017833) | M.D. Anderson Cancer Center | 2018-03-12 |
Track Refractory Neoplasm automatically
Every clearance here is in the API, with alerts when new ones post.